By:
On:
In: Policy Positions

The British Labour Party’s platform on access to health, “MEDICINES FOR THE MANY: Public Health before Private Profit,” is organized in five well-written and powerful policy chapters. In 52 pages, the Labour Party takes a strong stand defending patients instead of profits. It also provides a clear explanation of a new set of needed health policies, fully laying out rationale to implementation. The first chapter covers the current United Kingdom (UK) health system including the pricing of medicines. The second chapter deals with the many problems that plague the existing health care system from the lack of transparency to the pharmaceutical lobby. The third chapter,Read More →

By:
On:
In: News, Statements

UACT is disappointed by the preliminary rejection of Yescarta by the UK’s National Institute for Health and Care Excellence (NICE) over its high price, for two reasons: 1) Gilead is asking too much for the treatment which is largely based upon the US National Institutes of Health (NIH owned inventions, and 2) the UK government has not given any public indication it is considering alternatives to withholding coverage to address the problem of an excessive price. Yescarta is the Gilead trade name for axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor T-cell (CAR T) technology invented by the NIH, licensed to Kite/Gilead and approved by theRead More →